OBX02-011
CAS No. 2349336-18-9
OBX02-011( —— )
Catalog No. M28999 CAS No. 2349336-18-9
OBX02-011 is an effective and reversible inhibitor of EGFR tyrosine kinase with IC50s of 0.134 and 2.09 nM for triple mutants Del19/T790M/C797S and L858R/T790M/C797S.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 424 | Get Quote |
|
| 10MG | 635 | Get Quote |
|
| 25MG | 1143 | Get Quote |
|
| 50MG | 1715 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameOBX02-011
-
NoteResearch use only, not for human use.
-
Brief DescriptionOBX02-011 is an effective and reversible inhibitor of EGFR tyrosine kinase with IC50s of 0.134 and 2.09 nM for triple mutants Del19/T790M/C797S and L858R/T790M/C797S.
-
DescriptionOBX02-011 is an effective and reversible inhibitor of EGFR tyrosine kinase with IC50s of 0.134 and 2.09 nM for triple mutants Del19/T790M/C797S and L858R/T790M/C797S.(In Vitro):OBX02-011 shows broad activity at low nanomolar concentrations against mutant EGFRs. OBX02-011 occupies the ATP-binding site in a similar manner to WZ-4002.(In Vivo):In transgenic mouse models, OBX02-011 (25 mg/kg, i. p.) effectively inhibits tumor growth and EGFR activity and leads to enhanced survival.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2349336-18-9
-
Formula Weight615.19
-
Molecular FormulaC29H39ClN8O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=S(=O)(N(C=1C=CC=CC1NC2=NC(=NC=C2Cl)NC3=CC=C(C=C3OC)N4CCC(N5CCN(C)CC5)CC4)C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
RTC-5
RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.
-
TX1-85-1
TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling.
-
BPR1J-097
BPR1J-097 is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
Cart
sales@molnova.com